Transcript
**0:00** · Many of you have asked me for an update on Hims and Hers health. The stock is up 28% over the last few days. Massive, massive move. But this is by far one of the craziest stocks I've ever owned. It goes up like crazy and it goes down.**0:14** · Every time the stock goes down, people find all kind of reasons to sell it.**0:18** · Maybe the CEO said something or maybe whatever. And you could say I've been one of the most consistent people on YouTube in terms of talking about hems when it goes up and when it goes down because I've been in the stock from $7 per share in 2023 and I buy stocks for a reason with a certain thesis. If this thesis is no longer the same then I sell the stock and for him my thesis remains the same. So I'm still holding the company. Now for the latest news around peptide, it's really really bullish because they removed peptides from category 2 which will encourage peptide innovation. And based on my understanding, Hems is the only publicly traded telealth company. They actually owns a peptide facility. They were way ahead of the crowd and they acquired the peptide facility on February 21st of 2025 and they expect to use it to explore exciting advances in peptide innovation such as you know preventative health, metabolic optimization, cognitive performance, recovery science, biological resistance and many different things that could be implemented within peptide technology. And there was a recent interview with the CEO and he said something really funny. He said whenever the company was public, they were selling a lot of like Viagra and other kind of things. So they were calling him the Viagra company, you know. And then recently they've been calling it a weight loss company and maybe within one to two years from now they're going to call it a peptide company. So whatever the company is selling the most, they kind of label the company as this one product instead of looking at what actually him is selling which is hair loss, sexual health, mental health and weight loss also. And there are so many different things. It's not just a one product kind of company.**2:02** · But speaking about weight loss, the company has NVO pill right now at $149 a month, but it's not really at $149. This is $149 for the pill. But then there's another like $150 health related subscription, which I'm personally not a big fan of because it's got makes the company less competitive. But again, $150 will be like a membership where you get access 24/7. I believe they also give you access to labs and they cross sell you a lot of products within the hims and hers ecosystem. So, I'm not sure how that's going to play out, but it seems to be successful so far because the CEO said that they expect or they're on track to deliver more than 100,000 prescriptions of the Wiggoi product every month. So the $150 membership fee on top of the Wiggoi pill seems to be okay with most people. They want to pay it and maybe it helps them get more access to healthcare and it also help him crossell them many different things that they're suffering with and I've said it many times before that he will not make a lot of money on this pill but that should be a marketing funnel to crossell those people many different products. This is what RO health Roman health did. They increased their market share by a lot from about I believe it was here around 11% and they took it all the way up to 20% out of nowhere. Hims still has a 52% market share but our health has been expanding because they had access to the wig goi pill which everyone wanted. Now he has access to the wig pill and it's really transforming the company. If you look at the HERS business, which the Hers business has taken off in a major major way on the app store after they launched the pill, it's just the growth has been crazy. It has overtaken him in terms of growth. And if you look at the ranking, hers is now number five on the app store, sitting even ahead of Ro Health and ahead of the HIMS business for men.**4:02** · So women's business has taken off in a major major way whenever they announced the WGI pill. And you also have to take into consideration that the HERS pill or the HERS business hasn't really existed a few years ago. I remember him launching it. I believe it was in like 2022 2023 and people said it wasn't going to be successful. But again, it shows you that the company has done multiple things and and people said it was going to be successful and most of them ended up being a success. Now he is a much more diversified company. They have two and a half million subscribers in the United States. They have 1.3 about another like two and a half million in Europe. Total now they have 4.5 million subscribers from all around the world. It has massively diversified their total addressable market. 280 million United States, 200 million in Europe, Australia 20 million, Japan 100 million plus. Again, it's a much more diversified company. So if there's something that affects the company in United States, they still have the EU business and and Australia business and other businesses or if something happens there or they have the US business, they are taking it globally and I really love what Hims and Hers has done. I believe those international markets should massively increase the membership growth of HIMS. So, the number of subscribers have grown from like 555,000 to about 2 and a half million in the United States since 2021. It's been pretty pretty consistent and I would expect that to continue with the international expansion. Now, talking about the short interest, the short interest has finally started to go down and this is really, really good guys because whenever a company is shorted, it doesn't always mean that the shorts are dumb and they're missing something.**5:48** · A lot of them could actually not be missing something and they're shorting this specific stock for a reason. Maybe because it's overvalued, but it's mostly due to some, you know, related maybe to their policy, something due to the healthcare kind of policies or something do with the company. Something that's wrong with the company. This is why most short sellers short a stock, especially if it's a 44% short interest like what Hims had. Well, now it's down to 35%.**6:13** · 35% is still high but again the lower short interest goes the better it is which pretty much telling you that less and less people are seeing a reason to short hims especially after the partnership of NVO so for me it's not much about a short squeeze and the stocks going to go up to the moon people love saying those things on YouTube but does that really change the fundamentals of the company does it change the reason why I bought the company it doesn't really change it you know unless the stock goes up a th000% and they issue stock at $400 and then they use the cash to do something. I'm like, "Okay, that was good." But most cases, short interest, short squeeze is mostly like a waste of time because it doesn't really affect like the fundamentals of the company. Maybe it gives you an opportunity to sell, but but that's not why I'm investing in him and her health, you know. Now, for the valuation, despite the recent runup, Hims is still trading at almost 1.8 times sales. 1.8 Eight times sales for a company growing 30 40 50% revenues with an international business having the week goby pill expanding into labs launching new things peptides that's really really cheap guys for any kind of a growth for/sp speculative growth investment 1.8 eight times is really really cheap. Now if you look at the company's guidance, they're still guiding 6.5 billion by 2030 and this is at least 6 12 billion by 2030.**7:38** · So I use some assumptions of three times sales, five timesa sales and 10 times sales. If him trades at three times sales which is like in my opinion my worst case scenario if you compare it to any growth stock in the market no gross company with those metric is trading under three times sales. Now, if it trades under at three times sales, this is 250% on the upside. If it trades at five times sales, this is almost 490% on the upside. If it trades at 10 time sales, this is 1,080% on the upside.**8:10** · Now, 10 times sales might be like the most optimistic case scenario. If it was me, I would stick between three to five times sales. So I would see between 250 to 500% on the upside potentially over the next four to 5 years if the company delivers on on those promises in terms of revenue growth especially with the recent acquisitions and everything that's happening. I would not be surprised if they potentially exceed uh 6.5 billion. So for me I still own the company. I'm really excited to see what happens on the next earnings report. I'm going to be watching for subscriber growth. Watching for average order per subscriber, which has also been increasing, which is a really good sign of healthiness of cross-sellings of products within him's ecosystem. I'm also watching for any guidance around labs because labs will make it very very sticky and I'm holding it. It's a small percentage of my portfolio. I told you guys been in it since 2023 and I still own the stock and I'm in it for the long term. As long as the co doesn't do anything crazy, as long as nothing happened with my thesis, I'm gonna still be holding the stock despite what the CEO tweets or whatever happened that people like to focus on. I'm still in the company and I plan to hold it as long as the thesis remains intact. So that's my opinion on him and hers. Hope you enjoyed it. It was not financial advice. If you did enjoy it, please press the like button and maybe consider subscribing. So, I'll talk to you in another